Author: PharmaSignal News Desk

Obsidian Galera merger will trade on Nasdaq as OBX, securing $350 million in private placement.

Obsidian Galera merger results in Nasdaq listing under OBX, securing $350 million in private placement.

Travere FDA approval for Filspari marks a significant milestone, unlocking a $1 billion annual revenue opportunity in kidney disease.

J&J Q1 earnings reveal $15 billion in drug sales, driven by Tremfya and multiple myeloma treatments.

Lilly CrossBridge Bio deal enhances its ADC portfolio with dual-payload technology, valued at up to $300 million.

Revolution pancreatic cancer drug nearly doubles survival in Phase 3 trial, marking a significant advancement in treatment options.

Replimune FDA rejection highlights ongoing regulatory challenges for its melanoma drug, impacting potential market entry.

Lilly Foundayo Obesity Pill enters the US market, challenging Novo Nordisk’s three-month lead in oral obesity treatments.

Merck Terns acquisition secures leukemia drug rights after accepting a 15% lower offer amid competition from four bidders.

Gilead Tubulis acquisition marks a strategic move to enhance its ADC technology portfolio, valued at $3.1 billion.